Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer

NCT03641755 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03641755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03641755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 1, 2018
Completion date
October 22, 2026
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer